Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic Neoplasms
LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)-- Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today the launch of a newly established next generation sequencing service at the Summit Health laboratory in Woodland Park, NJ to offer comprehensive DNA and RNA profiling of solid tumors and hematologic neoplasms. The internalized GTC testing menu includes tissue and bone marrow-based DNA and RNA next generation sequencing of hematologic neoplasms and solid tumors. Summit Health will now offer GTC's peripheral blood and CSF-based liquid biopsy, Liquid Trace. This revolutionary liquid biopsy assay analyzes cell free DNA and RNA (cfDNA and cfRNA) for hematologic neoplasms and solid tumors. This testing provides Summit/Village MD clinicians with a comprehensive precision diagnosis and monitoring tools to deliver state-of-the-art precision care for their patients. By running the tests locally in-house, Summit Health will reduce their send-out burden to multiple labs, standardize collection of data, shorten turn-around time and have the opportunity to participate in R&D, clinical trials and the development of IP.
As a member of the GTC Co-Op group, Summit Health will gain access to cutting-edge scientific capabilities, access to a pipeline of innovation in diagnostics, and proprietary technology and datasets for R&D.
"We are very thrilled to partner with GTC in internalizing and adopting their comprehensive portfolio of tissue and liquid biopsy tests for hematologic neoplasms and solid tumors. We believe that this testing is currently essential for the practice of precision medicine,' said Dr. Gordana Katava, DO, Chief of Pathology and Laboratory Medicine, Summit Health/Village MD.
Dr. Maher Albitar, Founder, CEO and Chief Medical Officer at GTC, stated, 'We are excited to add Summit and Village MD physicians to our Co-Op network. GTC was established on the promise of democratizing genomic science and next generation sequencing. This partnership is a step forward toward achieving our goal,' Dr. Albitar added. 'The Co-OP model is not only standardizing next generation sequencing, but also providing ecosystem for cooperation, sharing knowledge and AI-based software, and reducing cost of internalizing NGS.'
About Summit Health
Summit Health, which is a part of VillageMD, helps patients with all their comprehensive primary care and multi-specialty care needs. Whether it's getting annual checkups, raising a family, or prioritizing healthy aging, Summit Health works as a team to deliver care that helps patients make the right choices and stay a step ahead of any issues. Summit Health offers high-quality connected care services covering nearly every medical specialty including orthopedics, urology, dermatology, cardiology, gastroenterology, and more. When patients need urgent care, they can visit Summit Health's urgent care partner, CityMD, which has 180+ locations throughout N.Y. and N.J. Together, Summit Health and CityMD are one connected care team.
About GTC
Genomic Testing Cooperative [GTC], the global leader in RNA innovation, is a privately owned molecular testing company located in Lake Forest, California. Since its inception in 2018 GTC has been focused on facilitating the acceleration of access to NGS enabled precision medicine in Oncology through innovative science and differentiated business models and practices and has grown through the realization of these strategies to become a leading partner/provider in the Oncology NGS space helping healthcare organizations to tackle the biggest problems in Next Generation Sequencing for Oncology today.
Forward Looking Statements
All the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on GTC and Summit Health management's current expectations and include statements regarding the value of Molecular profiling, testing, therapy, and the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and Summit Health or GTC undertake no duty to update this information unless required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
Fast Five Quiz: Cancer Diagnostics and Precision Medicine
Over the past decade, precision medicine has transformed cancer diagnostics and treatment by tailoring therapy to a patient's tumor biology based on molecular alterations rather than histologic subtypes or origins. Precision oncology often relies on molecular profiling through next-generation sequencing (NGS) to identify genomic events that can guide management. Techniques like targeted panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) provide different analysis levels, chosen based on tumor type, tissue, and therapy relevance. How much do you know about cancer diagnostics and precision medicine? Test your knowledge with this quick quiz. WGS is an NGS method that analyzes the entire DNA sequence of an organism, including both coding and noncoding regions. WGS offers broad genomic coverage, detecting structural variants, intergenic mutations, and copy number changes often missed by targeted methods. Clinically, it has been useful in identifying ERBB2 ( HER2 ) amplifications in breast cancer or complex epidermal growth factor receptor ( EGFR ) alterations in lung cancer that might not be captured by smaller panels, helping guide targeted therapy. However, its lower sequencing depth (30-60×) typically limits the detection of low-frequency variants in heterogeneous tumors, such as a subclonal TP53 mutation affecting a small subset of cells and potentially impacting treatment response, which WGS may miss due to its lower depth. WES focuses only on the protein-coding regions, offering greater depth than WGS but limited breadth; however, it misses important regulatory and noncoding mutations. For example, TERT promoter mutations in glioblastoma are clinically relevant but lie outside the exome and would be missed by WES. Targeted panels are NGS tests that focus on specific disease-related genes and, until recently, were the predominant method used for comprehensive genomic profiling in clinical settings. They offer high depth for detecting low-frequency, actionable mutations but have limited coverage and might miss rare alterations outside the selected genes. Sanger sequencing is a method that reads DNA by generating fragments of varying lengths using chain-terminating nucleotides. It is accurate for small regions but has low throughput and cannot detect low-frequency mutations, making it unsuitable for large-scale cancer genomics. Unlike WGS, which surveys the entire genome, Sanger covers only targeted regions, so it does not offer broad genomic coverage and is therefore not the correct answer. Learn more about molecular profiling in oncology diagnostics. TS panels analyze specific genes relevant to oncology, and by focusing on a smaller subset of the genome (a few dozen to a few hundred genes), these panels require fewer sequencing data, resulting in faster turnaround times and simplified data interpretation compared with WGS or WES. This targeted approach enhances sensitivity for detecting clinically actionable somatic mutations, especially in small or heterogeneous tumor samples. For example, targeted NGS panels in non-small cell lung cancer (NSCLC) can rapidly detect EGFR mutations, ALK rearrangements, and other actionable alterations, allowing oncologists to initiate targeted therapies based on the mutation profile promptly. TS also demands less data storage and computational processing compared with WGS or WES, resulting in faster turnaround times and lower costs. These attributes make TS especially well-suited for clinical settings where accuracy, speed, and cost-effectiveness are paramount Learn more about clinical practice guidelines in the use of precision medicine in oncology. Tissue is generally preferred for initial genomic profiling because it contains a higher concentration of tumor DNA, allowing for more accurate detection of somatic mutations. This is especially important in early-stage cancers or tumors that do not shed much DNA into the bloodstream to be detectable by liquid biopsy. The tissue also allows for additional analyses like immunohistochemistry for PD-L1 or assessment of tumor histology to guide therapy. Further, immunohistochemistry plays an important role in precision medicine by identifying protein biomarkers to help determine the use of immune checkpoint inhibitors in NSCLC, triple-negative breast cancer, and urothelial carcinoma. Blood-based tests (ie, liquid biopsies) generally yield lower tumor DNA and do not inherently offer deeper sequencing but are generally more cost-effective than tissue biopsies. Regulatory agencies currently accept blood-based tests (eg, FDA-approved liquid biopsies), but they are typically used when tissue is unavailable or there is insufficient tissue. Learn more about tissue-based profiling Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), has emerged as a valuable tool for monitoring MRD after treatment. By detecting small amounts of tumor-derived genetic material in the blood, liquid biopsy enables early identification of molecular relapse, often before clinical or radiographic evidence of recurrence is apparent. This makes it particularly useful in post-treatment surveillance of cancers such as colorectal, breast, and NSCLC. Diagnosing lymphomas typically requires tissue biopsy to assess architectural patterns and immunophenotyping; it is also commonly regarded as the standard for diagnosis. PD-L1 expression is a protein-based biomarker typically measured by immunohistochemistry on tissue samples, not usually through ctDNA. However, researchers have stated, 'ctDNA response is a potential biomarker for predicting the efficacy and prognosis of first-line PD-1 inhibitor therapy combined with chemotherapy' in patients with advanced gastric cancer. ctDNA also has been shown to predict responses in patients using PD-1/PD-L1 immune checkpoint inhibitors. Tumor staging usually relies on imaging modalities and pathologic evaluation rather than ctDNA analysis alone. Learn more about clinical practice guidelines in the use of precision medicine in oncology. A high TMB is considered useful because it is associated with abnormal proteins that make the tumor more recognizable to the immune system. TMB is measured using NGS by counting the number of somatic, nonsynonymous mutations per megabase of DNA; it is typically assessed using WES or large targeted panels. A TMB of 10 or more mutations per megabase is considered 'high,' based on data from the KEYNOTE-158 trial. This led to the FDA approval of an immune checkpoint inhibitor for TMB-high solid tumors, for example. High TMB is not usually linked to fewer side effects; side effect profiles tend to depend on the therapy, not mutation count. Low TMB has been shown to lead to fewer neoantigens and typically less immune visibility. Typically, TMB directly measures the number of mutations, not PD-L1 protein expression. Learn more about immunotherapy diagnostics.
Yahoo
4 days ago
- Yahoo
Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care
JACKSON HOLE, Wyo., June 18, 2025 /PRNewswire/ -- Healthy Interactions LLC, a global leader in experiential education for healthcare professionals and patients with cardiometabolic diseases, is accelerating its efforts to transform primary care with the expansion of the Healthy Interactions Primary Care Alliance. This Healthy Interactions Primary Care Alliance aims to enhance standards of care and clinical outcomes for patients with cardiometabolic conditions, with a particular focus on obesity. Through innovative Practice and Patient Obesity Virtual Conversation Map® programs, plus AI—the Alliance supports both healthcare professional and patient education. Currently, over 2,000 forward-thinking primary care practices have joined the Alliance, unified by a commitment to improving diagnosis, treatment adherence, and outcomes. Today, Healthy Interactions is pleased to announce that VillageMD, a national leader in value-based primary care, will join the Alliance and adopt Healthy Interactions' educational programs across hundreds of its practices nationwide. This collaboration represents a strategic opportunity for both organizations to advance their shared mission of improving care for patients with cardiometabolic conditions across America. "We are thrilled to build on our global success in improving care and outcomes for millions of patients with diabetes by expanding our obesity education programs for both primary care practices and patients," said Paul Lasiuk, CEO & Co-founder of Healthy Interactions. "Together, VillageMD and Healthy Interactions aim to improve diagnosis rates, increase care plan adherence, and drive better outcomes for people living with obesity." About Healthy InteractionsHealthy Interactions LLC is a global leader in experiential education programs focused on cardiometabolic health. The organization is known for its Conversation Map® platform, which blends visual learning with Socratic dialogue to engage patients meaningfully. In addition to its in-person and virtual education tools, Healthy Interactions is also expanding its impact through the development of AI-powered platforms designed to support healthcare professionals and patients in managing chronic conditions more effectively. With a presence in 129 countries and over 50 million lives impacted, Healthy Interactions continues to raise the bar in both healthcare professional and patient education. To learn more, please visit Media Contact:Shelly LeonardEmail: Sleonard@ Executive Contact:Paul LasiukCEO & Co-founder, Healthy InteractionsEmail: paullasiuk@ View original content: SOURCE Healthy Interactions, Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Nvidia (NVDA) Continues to Fire on All Cylinders
Nvidia Corp. (NASDAQ:NVDA) is one of the 10 best growth stocks to buy according to billionaires. Today, Nvidia's dominance in powering data centers and AI infrastructure is virtually uncontested. The demand for its GPUs not only boosted the growth of AI-driven applications but also led to tremendous growth for the company. In fiscal year 2021, the Gaming segment accounted for approximately 50% of total revenue. Over the next four years, the Data Center business surpassed it, accounting for around 89% of total revenue, while Gaming's contribution declined to around 9% by 2025. At its recently concluded GTC conference in Paris, the company highlighted its collaboration with European telecommunications companies, cloud service providers, and supercomputing centres in building AI infrastructure in the region. This accelerated investment by the EU is also expected to include building 20 AI Factories, among which 5 are Gigafactories. Therefore, Nvidia is expected to continue running at full speed. While the stock seems to be taking a breather in 2025 after the 170% surge in 2024, the majority of the street remains bullish, with the consensus 1-year median price target still indicating over 20% upside. Among the bullish voices is Oppenheimer analyst Rick Schafer, who on June 15, reiterated a Buy rating on Nvidia with an unchanged price target of $175. Before that, on June 12, DBS analyst Fang Boon Foo reiterated a Buy rating on Nvidia Corp. (NASDAQ:NVDA) but revised the price target to $160 from $175. The analyst highlighted that Nvidia's recent partnership with Mistral AI, a French company, and its expansion plans in Europe support Nvidia's solid market position. Although he lowered the price target, the analyst still sees strong growth potential for Nvidia, and cited healthy demand, solid margins, and a strong capital spending cycle across major tech firms as key drivers for the stock's long-term performance. Nvidia Corp. (NASDAQ:NVDA) is a leading innovator in the design and production of graphics processing units (GPUs), system-on-a-chip (SoC) solutions, and AI-driven hardware and software. The company's GPUs are used in gaming, high-performance computing, AI training, and inference and serve as the backbone of data center infrastructure worldwide. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
